This analysis in RR MCL shows CAR T-cell therapy (brexucabtagene) yields higher complete responses vs bispecific antibodies; durability remains unclear.
|Articles|August 1, 2008
The American Journal of Managed Care
- August 2008
- Volume 14
- Issue 8
Participant Disclosure (Am J Manag Care. 2008;14[suppl 8]:S241-S268)
Advertisement
Our July 2008 supplement on Biologics and Benefit Design, funded by Amgen Inc, (Am J Manag Care. 2008;14[suppl 8]:S241-S268), included an error of omission on the Participant Disclosures page.
The following disclosures for Robert Berglund should have been noted on S244:
Robert Berglund
Honoraria, Amgen Inc
Articles in this issue
about 18 years ago
A Meta-analysis Update: Percutaneous Coronary Interventionsabout 18 years ago
Medicare HMO Impact on Utilization at the End of Lifeabout 18 years ago
Flunking Asthma? When HEDIS Takes the ACTAdvertisement
Related to this article
Meta-analysis finds oral JAK inhibitors like baricitinib and ritlecitinib drive strong alopecia areata hair regrowth, improving SALT scores with manageable safety.
Follitropin delta yields cumulative ongoing pregnancy in 64.0% of patients under 35 and 43.9% of those 35 to 42 in 2 placebo-controlled IVF trials.
The Ambulatory Specialty Model aims to reduce chronic disease costs by mandating specialist participation and tying payments to quality and cost, while posing nationwide risk challenges.
Medicare drug price negotiations lowered out-of-pocket costs for some beneficiaries, but those reaching the annual Part D cap saw no direct savings.
AI quantitative CT (UCLA QILD, Brainomix e-Lung) predicts FVC decline and drug response in PPF, strengthening biomarkers beyond spirometry in INBUILD.
Delphi consensus guides dermatology on spotting CTCL vs atopic dermatitis before/after dupilumab, using biopsy plus T-cell clonality testing and safer treatment switches.
Rosacea is likely missed, not rare, in skin of color, as low suspicion and hard-to-see redness delay diagnosis, said Hilary Baldwin, MD.
Advertisement
Advertisement
Trending on AJMC
1
Medicare Drug Price Negotiations Yield Uneven Out-of-Pocket Savings
2
Lymphoma Outcomes Hinge on Oncology, Not Viral Load In People With HIV
3
Rusfertide Keeps Working Where Hydroxyurea Fades: Andrew Kuykendall, MD
4
New Mechanism of DME Treatment Highlights Clinical Trial Updates
5